Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis

Yu, Andrew P.; Yang, Hongbo; Wu, Eric Q.; Setyawan, Juliana; Mocarski, Michelle; Blum, Steven I.

doi:10.3111/13696998.2011.576295

Cited by 49 publications

(36 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A history of E-COPD therefore suggests a future frequent exacerbator phenotype, which leads to higher healthcare costs and use, as recent US studies have reported. [10], [12], [28] Furthermore, the healthcare costs increased in proportion to the severity of E-COPD, since a severe exacerbation requires hospitalization, at an average cost in our study of 3985 €, which is consistent with previous data. [29].…”

Section: Discussionsupporting

confidence: 92%

The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients

et al. 2014

View full text Add to dashboard Cite

BackgroundChronic Obstructive Pulmonary Disease (COPD) is a common disease with significant health and economic consequences. This study assesses the burden of COPD in the general population, and the influence of exacerbations (E-COPD) on disease progression and costs.MethodsThis is a secondary data analysis of healthcare administrative databases of the region of Lombardy, in northern Italy. The study included ≥ 40 year-old patients hospitalized for a severe E-COPD (index event) during 2006. Patients were classified in relation to the number and type of E-COPD experienced in a three-year pre-index period. Subjects were followed up until December 31st, 2009, collecting data on healthcare resource use and vital status.Results15857 patients were enrolled –9911 males, mean age: 76 years (SD 10). Over a mean follow-up time of 2.4 years (1.36), 81% of patients had at least one E-COPD with an annual rate of 3.2 exacerbations per person-year and an all-cause mortality of 47%. A history of exacerbation influenced the occurrence of new E-COPD and mortality after discharge for an E-COPD. On average, the healthcare system spent 6725€ per year per person (95%CI 6590–6863). Occurrence and type of exacerbations drove the direct healthcare cost. Less than one quarter of patients presented claims for pulmonary function tests.ConclusionsCOPD imposes a substantial burden on healthcare systems, mainly attributable to the type and occurrence of E-COPD, or in other words, to the exacerbator phenotypes. A more tailored approach to the management of COPD patients is required.

show abstract

Section: Discussionsupporting

confidence: 92%

The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…COPD patients using multiple long-acting maintenance inhalers (two or more prescriptions) have also been shown to be less adherent and have higher discontinuation rates than single-inhaler users [7]. Improving compliance among this patient population is particularly important, as poor adherence to drug therapy has been identified as the major factor resulting in emergency hospitalization among COPD patients [8–10].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Patient Preference and Willingness to Pay for Attributes of Maintenance Medication for Chronic Obstructive Pulmonary Disease (COPD)

Kawata

Kleinman

Harding

et al. 2014

Patient

View full text Add to dashboard Cite

BackgroundChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. COPD is characterized by poor treatment adherence, and patient medication preferences may contribute to adherence.MethodsA discrete choice experiment with an internet panel drawn from the USA was used to evaluate preference and willingness to pay (WTP) of COPD patients for long-acting maintenance medications. Key attributes derived from earlier qualitative research (brief literature review and focus groups) with COPD patients on maintenance therapy included symptom relief, speed of feeling medication start to work, inhaler ease of use, rescue medication use, side effects, and monthly out-of-pocket co-pay. Patients were presented with hypothetical medications with different profiles and asked which they preferred. Utilities and marginal WTP in monthly co-pay dollars were estimated for all patients and by severity.ResultsUtilities for 515 participants were in the expected direction and highest for the most favorable attribute levels. Each attribute evaluated was important, and participants were willing to pay a premium to obtain each benefit. On average, WTP was as high as $US64 for complete symptom relief, $US59 for no side effects, $US32 to rarely use rescue medication, $US16 for a quick and easy to use inhaler, and $US13 for feeling medication work quickly (within 5 min; average WTP $US18/month for patients with severe/very severe COPD).ConclusionAs expected, efficacy and safety were most valued by patients; however, this study showed that other COPD medication attributes, such as rescue medication, ease of use, and feeling medication work quickly, are also important in patient preferences.

show abstract

“…Thus, the current study findings should be interpreted with appropriate caution. COPD exacerbations are clinically meaningful events [4] with significant healthcare costs [24][25][26]. Considered the ''stroke of the lungs,'' COPD exacerbations initiate a catastrophic cascade of increased symptoms, decline in lung function, reduced exercise/physical function, increased hospitalization risk, lower quality of life, and accelerated disease progression [27].…”

Section: Discussionmentioning

confidence: 99%

Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations: USA Observational Cohort Study Using the Clinformatics™ Health Claims Database

et al. 2017

View full text Add to dashboard Cite

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis

Abstract: Exacerbations, especially severe ones, result in a significant economic burden for third-party payers. Effective management of COPD and prevention of exacerbations may lead to improved patient outcomes and reduction in total healthcare costs for long-term management of COPD.

Cited by 49 publications

References 26 publications

The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients

The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients

Evaluation of Patient Preference and Willingness to Pay for Attributes of Maintenance Medication for Chronic Obstructive Pulmonary Disease (COPD)

Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations: USA Observational Cohort Study Using the Clinformatics™ Health Claims Database

Contact Info

Product

Resources

About